MicroRNA-203a-3p improves bleomycin and pingyangmycin sensitivity by inactivating the PI3K/AKT pathway in hemangioma

被引:0
|
作者
Zhuo, Lei [1 ]
Hu, Zhenfeng [2 ]
Chang, Jin [1 ]
Guo, Qing [3 ]
Guo, Jing [4 ]
机构
[1] Hebei Univ Engn, Affiliated Hosp, Dept Plast Surg, Dept Gen Surg 4, Handan 056002, Hebei, Peoples R China
[2] Hebei Univ Engn, Dept Gen Surg 2, Dept Plast Surg, Affiliated Hosp, 81 Congtai Rd, Handan 056002, Hebei, Peoples R China
[3] Handan Cent Hosp, Wards Dept Oncol 4, Handan 056001, Hebei, Peoples R China
[4] Handan Cent Hosp, Wards Dept Cardiovasc Med 4, Handan, Hebei, Peoples R China
关键词
hemangioma; microRNA-203a-3p; bleomycin; pingyangmycin; PI3K/AKT pathway; INFANTILE HEMANGIOMA; CELL-PROLIFERATION; PROPRANOLOL; SCLEROTHERAPY; MANAGEMENT; APOPTOSIS; MIGRATION; THERAPY;
D O I
10.3892/etm.2024.12369
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
MicroRNAs (miRs) have been found to play a fundamental role in the pathology and progression of hemangioma. Of note, miR-203a-3p prevents hemangioma progression via inactivation of the PI3K/AKT pathway. Bleomycin and pingyangmycin are drugs used in sclerotherapy, but certain hemangioma patients experience drug resistance, leading to poor clinical outcomes. The present study aimed to explore the impact of miR-203a-3p on bleomycin and pingyangmycin sensitivity in hemangioma, as well as the involvement of the PI3K/AKT pathway. miR-203a-3p or negative control mimics were transfected into human hemangioma endothelial cells, which were treated with 0-20 mu M bleomycin or pingyangmycin. Subsequently, 740 Y-P, a PI3K/AKT pathway agonist, was added. Cell viability, rate of apoptosis and the expression levels of proteins involved in the PI3K/AKT pathway, including phosphorylated (p)-PI3K, PI3K, p-AKT and AKT, were detected. miR-203a-3p overexpression significantly decreased the half-maximal inhibitory concentration (IC50) values of bleomycin (5.84 +/- 0.87 vs. 14.23 +/- 2.17 mu M; P<0.01) and pingyangmycin (5.13 +/- 0.55 vs. 12.04 +/- 1.86 <mu>M; P<0.01), compared with untreated cells. In addition, under bleomycin or pingyangmycin treatment, miR-203a-3p overexpression significantly reduced the proportion of EdU positive cells (both P<0.05) and B-cell leukemia/lymphoma-2 (BCL2) protein expression levels (both P<0.05), whilst increasing cell apoptosis rate (both P<0.05) and cleaved caspase 3 protein expression levels (both P<0.05) compared with untreated controls. Furthermore, miR-203a-3p overexpression significantly inhibited the phosphorylation of PI3K and AKT (both P<0.05), an effect that was significantly diminished by 740 Y-P treatment (both P<0.01). In addition, 740 Y-P significantly increased IC50 values of bleomycin (P<0.01) and pingyangmycin (P<0.001) and also significantly increased the proportion of EdU-positive cells and BCL2 protein expression levels, while decreasing the apoptosis rate and cleaved caspase 3 protein expression levels in cells treated with bleomycin or pingyangmycin (all P<0.05). Of note, 740 Y-P weakened the effect of miR-203a-3p overexpression on the aforementioned cellular characteristics. The present study demonstrated that miR-203a-3p improved the sensitivity of cells to bleomycin and pingyangmycin treatment by inhibiting PI3K/AKT signaling in hemangioma.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] MicroRNA-203a-3p suppresses endothelial cell proliferation and invasion, and promotes apoptosis in hemangioma by inactivating the VEGF-mediated PI3K/AKT pathway
    Hu, Zhenfeng
    Zhuo, Lei
    Li, Yanling
    Duan, Dongpeng
    Guo, Jing
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (05)
  • [2] microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway
    Fan, Rong
    Zhong, Jie
    Zheng, Sichang
    Wang, Zhengting
    Xu, Ying
    Li, Shuyi
    Zhou, Jie
    Yuan, Fei
    CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 15 (02) : 137 - 144
  • [3] MicroRNA-328-3p inhibits the tumorigenesis of bladder cancer through targeting ITGA5 and inactivating PI3K/AKT pathway
    Yan, T.
    Ye, X-X
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (12) : 5139 - 5148
  • [4] SMAGP knockdown inhibits the malignant phenotypes of glioblastoma cells by inactivating the PI3K/Akt pathway
    Ni, Hongzao
    Ji, Daofei
    Huang, Zhixiong
    Li, Jing
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 695
  • [5] MicroRNA-93-5p promotes the progression of human retinoblastoma by regulating the PTEN/PI3K/AKT signaling pathway
    Cao, Yongliang
    Xia, Fei
    Wang, Ping
    Gao, Meng
    MOLECULAR MEDICINE REPORTS, 2018, 18 (06) : 5807 - 5814
  • [6] MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review
    Singh, Priyanka
    MEDICAL ONCOLOGY, 2023, 40 (10)
  • [7] Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway
    Shao, Hui
    Chen, Jingyan
    Li, Ali
    Ma, Lili
    Tang, Yongzhi
    Chen, Huazhong
    Chen, Yongping
    Liu, Junyan
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2023, 195 (08) : 5217 - 5237
  • [8] Oridonin Improves the Sensitivity of Multiple Myeloma Cells to Bortezomib through the PTEN/PI3K/Akt Pathway
    Wu, Hong
    Zhu, Guihua
    Su, Yizhou
    CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, 2020, 18 (03) : 292 - 296
  • [9] PI3K/Akt signalling pathway and cancer
    Vara, JAF
    Casado, E
    de Castro, J
    Cejas, P
    Belda-Iniesta, C
    González-Barón, M
    CANCER TREATMENT REVIEWS, 2004, 30 (02) : 193 - 204
  • [10] Isorhamnetin Improves Oocyte Maturation by Activating the Pi3k/Akt Signaling Pathway
    Li, Xiaoya
    Cheng, Jianyong
    Yao, Qichun
    Duan, Jiaxin
    Chen, Huali
    Zhang, Zelin
    Yang, Li
    Hua, Rongmao
    Li, Qingwang
    MOLECULAR NUTRITION & FOOD RESEARCH, 2024, 68 (15)